Tumor-specific T cells signal tumor destruction via the lymphotoxin β receptor

Table 4 The effect of LT-βR-Fc fusion protein administration on adoptive immunotherapy.

Adoptive immunotherapy ^a				Mean number of pulmonary metastases ^b
Donor T cells	Hosts	Number of T cells transferred	Blocking proteins^b
wt	wt	0	none	192(28)
wt	wt	35	none	0(0)
wt	wt	35	hu IgG	0(0)
wt	wt	35	LTβR-Fc	0(0)
PKO/GKO	wt	70	None	0(0)
PKO/GKO	wt	70	hu IgG	0(0)
PKO/GKO	wt	70	LTβR-Fc	78(50) ^d

a) Wild type (wt) or perforin and IFN-γ double deficient (PKO/GKO) mice were vaccinated s.c. with D5-G6 tumor cells and TVDLN were harvested 8 days later. Lymph node cells were stimulated in vitro with anti-CD3 for two days and then expanded for three days in 60 IU/ml IL-2. Effector cells were harvested and 35 × 10⁶ T cells were adoptively transferred into animals with established 3-day D5 pulmonary metastases. IL-2 (90,000 IU) was administered daily i.p. for four consecutive days following adoptive transfer.
b) Purified control human IgG or LT-βR-Fc (250 μg) was directly administered i.v. after adoptive transfer of the TE and for the following 3 days once per day.
c) Mice were sacrificed 13 days following i.v. inoculation of tumor and the number of pulmonary metastases enumerated in a blinded fashion. Results presented are the mean of 5 mice.
d) p < 0.05 compared to IL-2 alone treated controls.

ISSN: 1479-5876